Manulife (Manufacturers Life Insurance) Portfolio holdings
AUM
$112B
1-Year Return
19.76%
This Quarter Return
+0.78%
1 Year Return
+19.76%
3 Year Return
+56.91%
5 Year Return
+121.6%
10 Year Return
+261.3%
AUM
$122B
AUM Growth
-$1.01B
(-0.82%)
Cap. Flow
-$2.13B
Cap. Flow
% of AUM
-1.74%
Top 10 Holdings %
Top 10 Hldgs %
17.57%
Holding
3,330
New
114
Increased
1,022
Reduced
1,901
Closed
189
Top Buys
| 1 |
AB InBev
BUD
|
+$265M |
| 2 |
Royal Bank of Canada
RY
|
+$222M |
| 3 |
NVIDIA
NVDA
|
+$145M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$143M |
| 5 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$141M |
Top Sells
| 1 |
Bank of America
BAC
|
+$600M |
| 2 |
Telus
TU
|
+$454M |
| 3 |
SPDR S&P MidCap 400 ETF Trust
MDY
|
+$387M |
| 4 |
BPY
Brookfield Property Partners L.P. Limited Partnership Units
BPY
|
+$262M |
| 5 |
John Hancock Multifactor Developed International ETF
JHMD
|
+$223M |
Sector Composition
| 1 | Financials | 18.34% |
| 2 | Technology | 15.25% |
| 3 | Healthcare | 10.98% |
| 4 | Consumer Discretionary | 9.25% |
| 5 | Industrials | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2976
MediaAlpha
MAX
$672M
| $201K | ﹤0.01% |
10,783
-439
| -4% | -$8.18K |
|
2977
Spyre Therapeutics
SYRE
$1.03B
| $201K | ﹤0.01% |
1,013
-48
| -5% | -$9.52K |
|
2978
NVE Corp
NVEC
$324M
| $200K | ﹤0.01% |
3,122
-231
| -7% | -$14.8K |
|
2979
Occidental Petroleum Corporation Warrants to Purchase Common Stock
OXY.WS
$21.9B
| $200K | ﹤0.01% |
16,857
| – | – |
|
|
EGIO
2980
DELISTED
Edgio, Inc. Common Stock
EGIO
| $200K | ﹤0.01% |
2,099
+164
| +8% | +$15.6K |
|
2981
Full House Resorts
FLL
$123M
| $199K | ﹤0.01% |
18,775
-1,068
| -5% | -$11.3K |
|
2982
Arbutus Biopharma
ABUS
$805M
| $198K | ﹤0.01% |
46,204
-2,661
| -5% | -$11.4K |
|
2983
Pure Cycle
PCYO
$265M
| $198K | ﹤0.01% |
14,852
-1,222
| -8% | -$16.3K |
|
2984
AXT Inc
AXTI
$143M
| $197K | ﹤0.01% |
23,651
-586
| -2% | -$4.88K |
|
2985
Latham Group
SWIM
$951M
| $197K | ﹤0.01% |
12,004
-100,675
| -89% | -$1.65M |
|
2986
Tilly's
TLYS
$60.6M
| $197K | ﹤0.01% |
14,076
-656
| -4% | -$9.18K |
|
2987
KalVista Pharmaceuticals
KALV
$796M
| $196K | ﹤0.01% |
11,247
-474
| -4% | -$8.26K |
|
2988
Alto Ingredients
ALTO
$90.6M
| $194K | ﹤0.01% |
39,320
-1,429
| -4% | -$7.05K |
|
2989
Babcock & Wilcox
BW
$218M
| $194K | ﹤0.01% |
30,207
-969
| -3% | -$6.22K |
|
2990
CytomX Therapeutics
CTMX
$360M
| $194K | ﹤0.01% |
38,032
-1,249
| -3% | -$6.37K |
|
2991
Microvast
MVST
$932M
| $194K | ﹤0.01% |
+23,653
| New | +$194K |
|
2992
Instil Bio
TIL
$174M
| $193K | ﹤0.01% |
539
-24
| -4% | -$8.59K |
|
2993
Riverview Bancorp
RVSB
$106M
| $192K | ﹤0.01% |
26,448
| – | – |
|
2994
BeyondSpring
BYSI
$76.6M
| $191K | ﹤0.01% |
12,093
-3,761
| -24% | -$59.4K |
|
|
SQZ
2995
DELISTED
SQZ Biotechnologies Company
SQZ
| $191K | ﹤0.01% |
13,240
-667
| -5% | -$9.62K |
|
2996
Aligos Therapeutics
ALGS
$77.2M
| $190K | ﹤0.01% |
491
+48
| +11% | +$18.6K |
|
|
BZUN
2997
Baozun
BZUN
$227M
| $189K | ﹤0.01% |
10,800
+600
| +6% | +$10.5K |
|
2998
Lineage Cell Therapeutics
LCTX
$283M
| $189K | ﹤0.01% |
74,991
-3,053
| -4% | -$7.69K |
|
2999
Athira Pharma
ATHA
$15.4M
| $188K | ﹤0.01% |
20,014
+951
| +5% | +$8.93K |
|
3000
Lexicon Pharmaceuticals
LXRX
$392M
| $188K | ﹤0.01% |
39,070
-2,455
| -6% | -$11.8K |
|